		USD	INR (' In Thousands)	USD	INR (' In Thousands)
	Notes		As at 31 March 2020	3	As at 1 March 2019
ASSETS					
Non-current assets					
Intangible assets under development	1	10,95,019	82,854	10,56,440	73,063
Total non-current assets	_	10,95,019	82,854	10,56,440	73,063
Current assets					
Financial assets					
i. Trade receivables	2	-	-	10,56,440	73,063
ii. Cash and cash equivalents	3	37,212	2,816	-	-
Total current assets	_	37,212	2,816	10,56,440	73,063
Total assets	_	11,32,231	85,670	21,12,880	1,46,126
EQUITY AND LIABILITIES					
Equity					
Equity share capital	4	11,06,440	76,264	10,56,440	72,815
Other equity		(3,481)	7,191	(2,960)	43
Total Equity	_	11,02,959	83,455	10,53,480	72,858
LIABILITIES					
Current liabilities					
Financial liabilities					
i. Trade payables	4	29,272	2,215	10,59,400	73,268
Total current liabilities	_	29,272	2,215	10,59,400	73,268
Total liabilities		29,272	2,215	10,59,400	73,268
Total equity and liabilities	_	11,32,231	85,670	21,12,880	1,46,126

Benny Thomas Associate Vice President

Jubilant Episcribe LLC Statement of Profit and Loss for the year ended 31 March 2020

Statement of Front and Loss for the year ended 51 Ware	11 2020	USD	INR (' In Thousands)	USD	INR (' In Thousands)	
	Notes		or the year ended Fo 31 March 2020		For the year ended 31 March 2019	
Revenue from operations		-	-	-	-	
Total income		-	-	-	-	
Expenses						
Other expenses	5	521	37	2,960	209	
Total expenses		521	37	2,960	209	
Loss before tax		(521)	(37)	(2,960)	(209)	
Tax expense						
- Current tax		-	-	-	-	
- Deferred tax		-	-	-	-	
Total tax expense		-	-	-		
Loss for the year		(521)	(37)	(2,960)	(209)	
Other comprehensive income						
Items that will be reclassified to profit or loss						
Exchange differences on translation of foreign operations		-	7,185	-	252	
Other comprehensive loss for the year, net of tax		_	7,185	-	252	
Total comprehensive loss for the year		(521)	7,148	(2,960)	43	

Benny Thomas Associate Vice President

Jubilant Episcribe LLC Statement of changes in Equity for the year ended 31 March 2020

A) Equity Share Capital

, · · ·		USD
Balance as at 1 April 2018		-
Additions during the year		10,56,440
Balance as at 1 April 2019		10,56,440
Additions during the year		50,000
Balance as at 31 March 2020		11,06,440
B) Other Equity		HOD
	Reserves and Surplus	USD
	Retained earnings	Total
Balances as at 1 April 2018	-	-
Loss for the year	(2,960)	(2,960)
Total comprehensive loss for the year	(2,960)	(2,960)
Balances as at 31 March 2019	(2,960)	(2,960)
		USD
	Reserves and Surplus	
	Retained earnings	Total
Balances as at 1 April 2019	(2,960)	(2,960)
Loss for the year	(521)	(521)
Total comprehensive loss for the year	(521)	(521)
Balances as at 31 March 2020	(3,481)	(3,481)

Benny Thomas Associate Vice President

Jubilant Episcribe LLC Statement of changes in Equity for the year ended 31 March 2020

A) Equity Share Capital

A) Equity Share Capital			
			INR (' In
Dalamas as at 1 April 2010			Thousands)
Balance as at 1 April 2018 Additions during the year			72,815
Balance as at 1 April 2019			72,815
Additions during the year			3,449
Balance as at 31 March 2020			76,264
Datance as at 31 March 2020			70,204
B) Other Equity			
			INR (' In
			Thousands)
	Reserves and	Other	
	Surplus	Comprehensive	
		Income	
	D 4 1 1	Foreign currency	
	Retained	translation	Total
	earnings	reserve	
Balances as at 1 April 2018	_	_	_
Loss for the year	(209)	-	(209)
Other comprehensive loss for the year	<u>-</u>	252	252
Total comprehensive loss for the year	(209)	252	43
Balances as at 31 March 2019	(209)	252	43
			INR (' In
			Thousands)
		Other	1 nousunus)
	Reserves and	Comprehensive	
	Surplus	Income	
	Retained	Foreign currency	m
	earnings	translation	Total
		reserve	
Balances as at 1 April 2019	(209)	252	43
Loss for the year	(37)	-	(37)
Other comprehensive income for the year	-	7,185	7,185
Total comprehensive income for the year	(37)	7,185	7,148

(246)

7,437

7,191

Benny Thomas Associate Vice President

Balances as at 31 March 2020

Jubilant Episcribe LLC Statement of Cash Flows for the year ended 31 March 2020

Statement of Cash Flows for the year ended 51 Warch 2020					
	USD	INR (' In Thousands)	USD	INR (' In Thousands)	
	For th	ne year ended	For th	he year ended	
	31	March 2020		March 2019	
A. Cash flow from operating activities					
Loss before tax	(521)	(37)	(2,960)	(209)	
Operating cash flow before working capital changes	(521)	(37)	(2,960)	(209)	
Increase in trade and other receivables	-	-	(10,56,440)	(73,063)	
Increase in trade payables, provisions and other liabilities	481	34	10,59,400	73,268	
Cash used in operations	(40)	(3)	_	(4)	
Income tax and wealth tax paid (net of refund)		-	-		
Net cash used in operating activities	(40)	(3)	_	(4)	
B. Cash flow from investing activities					
Purchase of fixed assets	(12,748)	(902)	-	-	
Net cash generated from / (used in) investing activities	(12,748)	(902)	_		
C. Cash flow arising from financing activities					
Proceeds from issue of equity	50,000	3,539	-	-	
Net cash generated from financing activities	50,000	3,539			
D. Effect of exchange rate changes	-	182	-	4	
Net decrease in cash and cash equivalents (A+B+C+D)	37,212	2,816	_	-	
Add: cash and cash equivalents at the beginning of year		-	-		
Cash and cash equivalents at the end of the year	37,212	2,816	-		

Benny Thomas Associate Vice President

Note 1: Intangible assets under development

Trote 1. Intangible assets under development	USD	INR (' In Thousands)	USD	INR (' In Thousands)
		As at 31 March 2020		As at 31 March 2019
Intangible assets under development	10,95,019	82,854	10,56,440	73,063
Total Intangible assets under development	10,95,019	82,854	10,56,440	73,063
Note 2: Trade receivables	USD	INR (' In Thousands)	USD	INR (' In Thousands)
		As at 31 March 2020		As at 31 March 2019
Unsecured, considered good Trade receivables from related parties	-	-	10,56,440	73,063
Total trade receivables		-	10,56,440	73,063
Note 3: Cash and cash equivalents	USD	INR (' In Thousands)	USD	INR (' In Thousands)
		As at 31 March 2020		As at 31 March 2019
Balances with banks In current accounts Total cash and cash equivalents	37,212 37,212	2,816 2,816	-	<u>-</u>
Note 4 : Equity share capital	USD	INR (' In Thousands)	USD	INR (' In Thousands)
		As at 31 March 2020		As at 31 March 2019
Issued, subscribed and paid up Equity shares	11,06,440	76,264	10,56,440	72,815

¹⁾ The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitiled to one vote per share.

²⁾ In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

Jubilant Episcribe LLC

Notes to the financial statements for the year ended 31 March 2020 $\,$

3) The details of shareholders holding more than 5% shares in the Company:

			USD	INR (' In
		As at		As at
		31 March 2020		31 March 2019
	No of units	% holding in	No of units	% holding in the
		the class		class
Name of the Shareholder				
Jubilant Therapeutics Inc	105	100%	100	100%
4) The reconciliation of the number of shares outstanding as at beginning as	nd at end of the repor	ting period		
		As at		As at
		31 March 2020		31 March 2019
	No of units	USD	No of units	USD
Numbers of units at the beginning of the year	100	10,56,440	-	-
Add: Units issued during the year	5	50,000	100	10,56,440
Number of units at the end of the year	105	11,06,440	100	10,56,440
		As at		As at
		31 March 2020		31 March 2019
	No of units	INR (' In	No of units	INR (' In
		Thousands)		Thousands)
Numbers of units at the beginning of the year	100	72,815	-	-
Add: Units issued during the year	5	3,449	100	72,815
Number of units at the end of the year	105	76,264	100	72,815

5) Equity shares held by holding company/ultimate holding company is set out below:

Particulars	As at 31 March 2020	As at 31 March 2019
Jubilant Therapeutics Inc	No of units 105	No of units 100

Jubilant Episcribe LLC Notes to the financial statements for the year ended 31 March 2020

Note 5: Trade payables

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
		As at		As at
	3	31 March 2020		31 March 2019
Trade payables	2,081	158	2,000	138
Due to related parties	27,191	2,057	10,57,400	73,130
Total trade payables	29,272	2,215	10,59,400	73,268

Note 6: Other expenses

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
		As at 31 March 2020		As at 31 March 2019
Auditors remuneration	-	-	2,000	141
Legal and professional fees	-	-	960	68
Patent related expenses	81	6	-	-
Rates and taxes	400	28	-	-
Bank charges	40	3	-	-
Total other expenses	521	37	2,960	209